Ticker: NYSE: ANVS
Headquarters: Berwyn, Pennsylvania, USA
Founded: 2008
CEO: Michael Trout
Market Cap: ~$50M (2025)
Annovis Bio is a clinical-stage drug development company focused on developing novel therapies for Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders. The company's lead compound, buntanetap (formerly known as Posiphen and NPT200-1), is a translational inhibitor of multiple neurotoxic proteins including amyloid precursor protein (APP), alpha-synuclein, and tau[1].
| Trial | Phase | Indication | Status | ClinicalTrials.gov |
|---|---|---|---|---|
| AD-PD301 | Phase 2 | Alzheimer's disease | Completed | NCT04590833[2] |
| PD-301 | Phase 2 | Parkinson's disease | Completed | NCT04639011[3] |
| DIS | Phase 3 | Parkinson's disease | Planning | — |
Buntanetap works through multiple pathways[4][5]:
Unlike single-target approaches, buntanetap's multi-target profile addresses multiple pathological features of neurodegenerative diseases simultaneously, potentially providing broader therapeutic benefit.
Phase 2 Study of Buntanetap in Early Alzheimer's Disease - ClinicalTrials.gov NCT04590833. ↩︎
Phase 2 Study of Buntanetap in Parkinson's Disease - ClinicalTrials.gov NCT04639011. ↩︎
Carrara, M. et al. Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients. The Journal of Prevention of Alzheimer's Disease. 2023. ↩︎
Chen, W. et al. Targeting Increased Levels of APP in Down Syndrome: Posiphen-Mediated Reductions in APP and Its Products Reverse Endosomal Phenotypes. Alzheimer's & Dementia. 2021. ↩︎
Maccecchini, M.L. et al. Buntanetap in Early Alzheimer's Disease: Phase 2 Results. Alzheimer's & Dementia. 2023. ↩︎
Buntanetap in Parkinson's Disease: Phase 2 Clinical Outcomes. Neurology. 2023. ↩︎